CC
TSHA icon

Casdin Capital’s Taysha Gene Therapies TSHA Stock Holding History

Casdin Capital’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.5M Buy
3,250,000
+1,750,000
+117% +$8.14M 1.1% 18
2025
Q4 		$8.25M Buy
+1,500,000
New +$7.28M 0.51% 28
2021
Q2 		– Sell
-820,440
Closed -$16.7M – 58
2021
Q1 		$16.7M Hold
820,440
– – 0.5% 35
2020
Q4 		$21.8M Hold
820,440
– – 0.65% 34
2020
Q3 		$18.4M Buy
+820,440
New +$19.3M 0.82% 28

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Casdin Capital's TSHA Position: Q1 2026 in Review

Casdin Capital increased its Taysha Gene Therapies (TSHA) stake by 117% in Q1 2026, buying an estimated $8.14M and bringing the position to 3,250,000 shares worth $14.5M. The position accounts for 1.1% of the portfolio, ranked #18.

Casdin Capital first reported a position in TSHA in Q3 2020 and has held it in 5 quarters since. The position peaked at $21.8M in Q4 2020. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Casdin Capital held 3,250,000 shares of Taysha Gene Therapies worth $14.5M as of Q1 2026.
  • Casdin Capital bought 1,750,000 Taysha Gene Therapies shares in Q1 2026, an estimated $8.14M.
  • Taysha Gene Therapies made up 1.1% of Casdin Capital's portfolio in Q1 2026, its #18 holding.
  • Casdin Capital first reported a position in Taysha Gene Therapies in Q3 2020 and has held it in 5 quarters since.
  • Casdin Capital's Taysha Gene Therapies position peaked at $21.8M in Q4 2020.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Casdin Capital's 13F filing for Q1 2026, filed 15 May 2026.